Dr Emanuel Rognoni is a Biochemist by training and undertook a PhD in Pharmacology at the Department for Molecular Medicine, Max Planck Institute of Biochemistry in Munich focused on exploring the disease pathogenesis of the Epidermolysis bullosa (EB) subtype Kindler Syndrome. After a Postdoc with Prof Fiona Watt (Centre for Stem Cell and Regenerative Medicine, King’s College London) he started his independent research group at the Centre for Cell Biology and Cutaneous Research, Blizard Institute, QMUL.
The goal is to elucidate the fundamental biology defining fibroblast heterogeneity during skin regeneration and disease and develop preclinical in vivo disease models, paving the way for new treatment strategies in skin diseases, in particular EB. Together with his colleague Dr Matthew Caley, they have recently established the preclinical testing pipeline TREAT-EB at QMUL, to accelerate therapeutic development for EB patients